Summary
Pfizer Inc.'s 2008 Form 10-K filing highlights a year of significant strategic moves and robust performance despite challenges from patent expirations. The company maintained its position as a global pharmaceutical leader, with its Pharmaceutical segment contributing over 91% of total revenues, driven by strong performances from key products like Lipitor and Lyrica. However, the loss of U.S. exclusivity for Norvasc and patent expirations for other major drugs presented headwinds. Pfizer also made substantial investments in research and development, totaling $7.9 billion, to fuel its future pipeline. A major announcement in early 2009, the definitive merger agreement to acquire Wyeth for $68 billion, signals a significant future growth strategy aimed at expanding its product portfolio and global reach. Operationally, Pfizer demonstrated resilience with international revenues accounting for a substantial 57.7% of total revenue, benefiting from favorable foreign exchange rates. The company navigated a complex regulatory environment and increasing pricing pressures from managed care organizations and government programs. Key product successes in both the Pharmaceutical and Animal Health segments underscore Pfizer's diversified strengths, while strategic acquisitions throughout 2008 aimed to bolster its presence in areas like immunotherapy and central nervous system disorders.
Financial Highlights
53 data points| Revenue | $48.30B |
| Cost of Revenue | $8.11B |
| Gross Profit | $40.18B |
| SG&A Expenses | $14.54B |
| Operating Income | $8.03B |
| Interest Expense | $516.00M |
| Net Income | $8.10B |
| EPS (Basic) | $1.20 |
| EPS (Diluted) | $1.20 |
| Shares Outstanding (Basic) | 6.73B |
| Shares Outstanding (Diluted) | 6.75B |
Key Highlights
- 1Pharmaceutical segment remains the dominant revenue driver, accounting for 91.5% of total revenues in 2008.
- 2Significant R&D investment of $7.9 billion in 2008, with 106 projects in development, indicating a strong focus on future innovation.
- 3Announced a definitive merger agreement to acquire Wyeth for $68 billion in January 2009, a major strategic move for future growth and portfolio expansion.
- 4International operations are substantial, generating 57.7% of total revenues in 2008, with positive impacts from foreign exchange.
- 5Experienced revenue decline in the Pharmaceutical segment due to loss of exclusivity for key drugs like Norvasc and Camptosar.
- 6Key products such as Lipitor, Lyrica, and Celebrex continued to perform strongly, alongside growth in the Animal Health segment.
- 7Company is actively managing patent expirations and defending key patents against legal challenges, particularly for Lipitor.